Cargando…

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progression-free survival and toxicity. Between October 1992 and April 1995, 455 patients with 5-FU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freyer, G, Rougier, P, Bugat, R, Droz, J-P, Marty, M, Bleiberg, H, Mignard, D, Awad, L, Herait, P, Culine, S, Trillet-Lenoir, V
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374663/ https://www.ncbi.nlm.nih.gov/pubmed/10945486 http://dx.doi.org/10.1054/bjoc.2000.1303

Ejemplares similares

Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
por: Lin, Xiaoxi B., et al.
Publicado: (2012)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity
por: Levi, Mattan, et al.
Publicado: (2022)

CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
por: Guichard, S, et al.
Publicado: (1999)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.
por: Tsuda, H., et al.
Publicado: (1994)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
por: Van Cutsem, E, et al.
Publicado: (2005)

Consumption of an omega-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice
por: Hardman, W E, et al.
Publicado: (2002)

Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
por: Sadzuka, Yasuyuki, et al.
Publicado: (1999)

Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
por: Leonard, P, et al.
Publicado: (2002)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
por: Akhoundova Sanoyan, Dilara, et al.
Publicado: (2020)

Investigation of the Possible Protective Effect of N-Acetylcysteine (NAC) against Irinotecan (CPT-11)-Induced Toxicity in Rats
por: Gençosman, Sevgi, et al.
Publicado: (2022)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects
por: Hardman, W E, et al.
Publicado: (1999)

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
por: Dumez, Herlinde, et al.
Publicado: (2009)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
por: Schoemaker, N E, et al.
Publicado: (2004)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma
por: Bathe, Oliver F, et al.
Publicado: (2004)

MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts
por: Honorat, Mylène, et al.
Publicado: (2015)

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
por: Delord, J-P, et al.
Publicado: (2007)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
por: Buhl, Ida Kappel, et al.
Publicado: (2016)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
por: Kikuchi, Koji, et al.
Publicado: (2022)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Cold antihydrogen and CPT
por: Gabrielse, G, et al.
Publicado: (2002)

Tests of CPT with CPLEAR
por: Adler, R, et al.
Publicado: (1996)

CP, T and CPT at CPLEAR
por: Filipcic, Andrej, et al.
Publicado: (2001)

Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells.
por: Herait, P., et al.
Publicado: (1987)

Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF
por: Woo, Jong Kyu, et al.
Publicado: (2015)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
por: Mabro, M, et al.
Publicado: (2006)

Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
por: Bibby, M. C., et al.
Publicado: (1981)

Experimental tests of CPT invariance
por: Zavrtanik, D, et al.
Publicado: (2000)

Tests of CP and CPT invariance at LEAR
por: Gumplinger, P
Publicado: (1989)

Tests of CPT invariance in the CPLEAR experiment
por: Bloch, P
Publicado: (2001)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2fco5g5t3rcrfdi9k4d26anbnm